https://data.mendeley.com/datasets/xhfzxp9nfp/1
Supplement: Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic...
Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score-matched cohort study
https://iris.unito.it/handle/2318/1951732
Long-Term Efficacy and Safety of Dupilumab in Patients with Atopic Dermatitis: A Single-Centre...
https://newshealth.biz/health-news/dupilumab-approved-for-allergic-fungal-rhinosinusitis/
Dupilumab Approved for Allergic Fungal Rhinosinusitis | News Health
Feb 25, 2026 - The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older. Medscape Medical News Source link :
dupilumabapprovedallergicfungalnews
https://ctv.veeva.com/study/grass-pollen-immunotherapy-plus-dupilumab-for-tolerance-induction
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
The primary objective of this study is to assess whether the combination of grass allergen sublingual immunotherapy (SLIT) and dupilumab for 2 years is more...
grass pollenimmunotherapyplusdupilumabtolerance
https://www.delveinsight.com/blog/tag/dupilumab-drug-insight
Dupilumab drug Insight Archives - DelveInsight
Insights into the latest healthcare news and happenings in the Dupilumab drug Insight published on DelveInsight
dupilumabdruginsightarchives
https://www.epistemonikos.org/en/documents/cf79e909942467d439d179b88f3b42291cbc066e
Dupilumab treatment improved sleep quality in moderate-to-severe atopic dermatitis in children aged...
Sleep disturbance is a major factor leading to reduced quality of life of pediatric patients and their caregivers. LIBERTY AD INFANT/PRESCHOOL (NCT03346434 p...
https://pubmed.ncbi.nlm.nih.gov/38985486/
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study
In this study, there was sustained safety and efficacy of continuous long-term dupilumab treatment for adults with moderate to severe AD.
https://www.themednet.org/what-factors-do-you-weigh-most-heavily-when-deciding-on-the-duration-of-treatment-with-dupilumab-in-a-patient-with-atopic-dermatitis-who-is-responding-well-and-tolerating-therapy?from=dermatology
What factors do you weigh most heavily when deciding on the duration of treatment with dupilumab in...
Physician discussion: What factors do you weigh most heavily when deciding on the duration of treatment with dupilumab in a patient with atopic dermatitis who...
https://www.iltirreno.it/ultimora-adnkronos/2026/01/30/news/cattani-sanofi-con-bpco-diventano-11-le-indicazioni-per-dupilumab-1.100824804
Cattani (Sanofi): "Con Bpco diventano 11 le indicazioni per dupilumab" - Il Tirreno
https://adisinsight.springer.com/drugsafety/803924925?error=cookies_not_supported&code=84dab236-80ad-4f62-a0a9-b57d80854131
Dupilumab - AdisInsight
Adults and adolescents with moderate-to-severe atopic dermatitis experienced lack of efficacy during treatment with dupilumab, as evidenced by failure to
dupilumabadisinsight
https://www.indehuidvan.nl/atopisch-eczeem/behandeling-medicatie/biologicals/dupilumab/
Dupilumab - In de huid van
dupilumabdehuidvan
https://research.regionh.dk/da/publications/dupilumab-treatment-in-two-patients-with-severe-allergic-contact-/
Dupilumab treatment in two patients with severe allergic contact dermatitis caused by sesquiterpene...
allergic contact dermatitis
https://research.uniupo.it/it/publications/influence-of-prior-endoscopic-sinus-surgery-extent-on-dupilumab-e/
Influence of Prior Endoscopic Sinus Surgery Extent on Dupilumab Effectiveness in CRSwNP Patients -...
endoscopic sinus surgery
https://www.ejpd.com/index.php/journal/article/view/2921
Dupilumab-induced osteomuscular syndrome in a child with atopic dermatitis. | European Journal of...
https://iris.unito.it/handle/2318/1815267
Dupilumab-induced Urticaria
dupilumabinducedurticaria
https://www.ncfinternational.it/atopic-dermatitis-positive-dupilumab-topline-results-two-phase-3-trials/
Atopic dermatitis: a positive dupilumab topline results from two phase 3 trials - NCF International
Jun 20, 2016 - Dupilumab is first systemic therapy to show positive Phase 3 results in patients with moderate-to-severe atopic dermatitis, a serious, chronic inflammatory...
https://www.clinicaltrialsarena.com/projects/dupixent-dupilumab-atopic-dermatitis/
Dupixent (dupilumab) for the Treatment of Atopic Dermatitis, US
Oct 18, 2023 - Dupixent (dupilumab) is for the treatment of moderate to severe atopic dermatitis and asthma in adults and children.
for theatopic dermatitisdupixentdupilumabtreatment
https://www.vannoortevents.com/2024/08/29/anti-il-4ra-dupilumab-biosimilarmab/
Anti-IL-4RA (dupilumab biosimilar)mAb | NotchInhibitornotchinhibitor
Aug 29, 2024 - Name : Anti-IL-4RA (dupilumab biosimilar)mAbUniprot ID : P24394Common Name : REGN668, SAR23189Synonyms : CD124;IL-4RA;IL4RAApplication : ELISA; Flow...
antiilmab